Former NIH scientist J. Bart Classen who was previously in research claimed that mRNA vaccines could potentially cause prion diseases now; a new study said U.K. data reveals evident signs that back his allegations.
Prion diseases involve a range of neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA). The production and aggregation of misfolded proteins within the brain system are typically linked to these illnesses.
Dr. Classen’s latest research, released on July 18, particularly employed six months of data from the U.K. government’s version of the adverse event reporting system, Yellow Card.
Although both vaccines are supposed to stimulate the development of coronavirus spike protein and associated antibodies in the recipient, Classen said the two injections were very distinct in their content, according to Life Site News.
Considering their potential ability to cause build-up neurodegenerative disorders to recipients in the long run, Classen’s analysis discovered that AstraZeneca poses much greater risks than Pfizer. In general, each AstraZeneca report had an average of 3.63 adverse events, compared to 2.84 adverse reactions per Pfizer report.
Similar patterns repeated for reports of prion diseases related symptoms.
In the “Nervous Disorders” category, AstraZeneca came out with 4.14 times the number of such reactions recorded for the Pfizer jab.
With Parkinson’s reactions, AstraZeneca came out with 185 reports, whereas Pfizer only had 20 cases. Reports of tremor in the former vaccine stood at 9,288 cases, nearly ten-folds of that presented in the later vaccine (937 cases). Meanwhile, reports of sleep disturbances in Pfizer were modest at 4 counts, whereas for AstraZeneca the number was 58 cases.
These symptoms, as Dr. Classen noted were clear indicators of Parkinson’s disease.
About the disparities in reports between the two vaccines, Dr. Classen admitted he did not have the precise number of doses distributed by each brand. But he thought the threats of prion diseases potentially caused by the vaccines might be nonetheless the same.
“The AstraZeneca … vaccine may concentrate in the gastrointestinal system to a greater extent leading to faster transport of the spike protein via the vagus nerve to the brain. By contrast over the long run, the Pfizer mRNA vaccine may induce more TDP-43 and FUS to form prions and lead to more prion disease,” he explained.
In his February report, Classen suggested that “the folding of TDP-43 and FUS into their pathologic prion confirmations is known to cause ALS, frontotemporal lobar degeneration, Alzheimer’s disease, and other neurological degenerative diseases.”
This is not good news for patients who already have preclinical prion disease or who have mild prion disease that had not been identified.
Normally, such illnesses would take years (or decades) to start and affect patients. Now with the catalyst of the spike proteins, as Dr. Classen anticipated, would boost prion diseases to happen much faster than usual.
Still, because neurodegenerative diseases take a longer time to develop than the other acute events and are much less noticeable than the other conditions, Dr. Classen believes the reporting systems may not reflect the real scope of these side effects.